Cantor Fitzgerald reiterates Oklo stock rating on execution progress By Investing.com

Cantor Fitzgerald reiterated an Overweight and $122 12-month target on Oklo (current price $60.53), implying >100% upside while the shares are down 42% over the past six months. Oklo reported a full-year operating loss of $139.3M, finished the year with $1.4B in cash (supporting runway for a pre-revenue nuclear technology company), and cited regulatory progress on Aurora INL, the A3F fuel facility and Groves Isotope test reactor; InvestingPro notes the stock appears overvalued versus its fair value.

Analysis

A successful regulatory path for a first-of-a-kind advanced reactor developer likely re-routes value toward upstream suppliers (fuel fabrication, HALEU enrichment, specialized steam turbine and control vendors) and midstream integrators (utilities that can host small reactors). Incumbent industrial suppliers with existing supply chains and licensing track records can convert regulatory tailwinds into durable cash flows faster than greenfield builders, creating a two-tier winner list: ‘manufacturing and services’ vs ‘project-developer optionality’.

Key tail risks cluster around three choke points: HALEU supply timing, construction and commissioning cost overruns, and insurance/utility-offtake appetite. Each is a multi-quarter to multi-year friction — a delay in HALEU availability or a single well-publicized commissioning failure could reset implied valuations across early-stage developers within months and force recapitalizations.

The optimal capital strategy for the fund is optionality with controlled downside: express a convex bet on milestone delivery (licensing, fuel qualification, first grid connection) while hedging exposure to realized execution risk. Market structure favors buying long-dated asymmetric payoffs (LEAP call spreads) or taking spread exposure between OEM/supplier equities and raw developer equity, rather than naked long positions.

Consensus is underweighting the speed at which incumbents will monetize demand (through long-term supply contracts, IP licensing, and service margins) and overestimating the irrelevance of fuel and component bottlenecks. That creates a structural arbitrage: pay for concentrated upside on developers, but collect carry in the supplier/utility complex that will realize most near-term cash flows.

Key Decisions for Investors

• Buy asymmetric optionality on OKLO: purchase 18–30 month call spreads (LEAP calls long, higher-strike calls short) sized to 1–2% net NAV to capture regulatory/catalyst upside while limiting premium paid. Target 3x+ payoff if licensing milestones and a fuel qualification event occur within 12–24 months; downside capped to premium.
• Pair trade: long BWXT (industrial nuclear supplier) + short OKLO equity (or buy OKLO puts) in a 1:0.5 dollar-weighted ratio over 6–18 months. Rationale: suppliers should capture recurring service and component margins even if developers reprice lower; target asymmetric return of 20–40% vs limited carry cost (monitor supplier execution).
• Tactical uranium exposure: add a 12–36 month overweight to a major uranium producer (e.g., CCJ) sized 1–2% NAV to play rising HALEU/uranium demand if modular deployment accelerates. Risk: uranium price exposure and weak spot demand; trim on a 25–35% run-up or if deployment timelines slip >12 months.
• Downside hedge: buy 6–12 month protective puts on OKLO (or buy vol via short-dated puts) equal to 1–2% NAV to insure against licensing failure, financing dilution, or a negative commissioning event. Exit or roll if a clear multi-month recovery in sentiment follows a positive regulatory pass.